Cargando…

Tocilizumab Use among Patients Who Developed Pulmonary Embolism in the Course of Cytokine Release Storm and COVID-19 Pneumonia—A Retrospective Study

Introduction: Thromboembolic events, including mainly pulmonary embolisms and ischemic strokes, occur in up to one-third of COVID-19 patients. As efficacy of tocilizumab (TCZ) among patients with acute pulmonary embolism (PE) was not previously investigated, this study aimed to provide such data. Ob...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chober, Daniel, Aksak-Wąs, Bogusz, Niścigorska-Olsen, Jolanta, Niekrasz, Małgorzata, Parczewski, Miłosz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313102/ https://www.ncbi.nlm.nih.gov/pubmed/35884886 http://dx.doi.org/10.3390/biomedicines10071581

Ejemplares similares

Effectiveness of Tocilizumab in Patients with Severe or Critical Lung Involvement in COVID-19: A Retrospective Study
por: Chober, Daniel, et al.
Publicado: (2022)

Septic Shock Induced by Vibrio Vulnificus in Northern Poland, a Case Report
por: Aksak-Wąs, Bogusz Jan, et al.
Publicado: (2021)

Remdesivir Reduces Mortality in Hemato-Oncology Patients with COVID-19
por: Aksak-Wąs, Bogusz Jan, et al.
Publicado: (2022)

Phylodynamic Dispersal of SARS-CoV-2 Lineages Circulating across Polish–German Border Provinces
por: Serwin, Karol, et al.
Publicado: (2022)

Improved survival in intensive care unit in severe COVID-19 associated with amantadine use - retrospective study
por: Chober, Daniel, et al.
Publicado: (2022)

Factors Influencing Immune Restoration in People Living with HIV/AIDS
por: Aksak-Wąs, Bogusz Jan, et al.
Publicado: (2022)

Protective Effect of HLA-B*5701 and HLA-C -35 Genetic Variants in HIV-Positive Caucasians from Northern Poland
por: Leszczyszyn-Pynka, Magdalena, et al.
Publicado: (2015)

Influence of HLA-B*5701 on 20 year survival rate among patients living with HIV
por: Aksak-Wąs, Bogusz Jan, et al.
Publicado: (2021)

Correction: Influence of HLA-B*5701 on 20 year survival rate among patients living with HIV
por: Aksak-Wąs, Bogusz Jan, et al.
Publicado: (2022)

COVID-19-Associated Encephalopathy—Case Series and Clinical Considerations
por: Udzik, Jakub, et al.
Publicado: (2022)

Hepatotropic Properties of SARS-CoV-2—Preliminary Results of Cross-Sectional Observational Study from the First Wave COVID-19 Pandemic
por: Wiśniewska, Hanna, et al.
Publicado: (2021)

Immune Signature of COVID-19: In-Depth Reasons and Consequences of the Cytokine Storm
por: Niedźwiedzka-Rystwej, Paulina, et al.
Publicado: (2022)

Can tocilizumab calm the cytokine storm of COVID-19?
por: Schulert, Grant S
Publicado: (2020)

Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?
por: Antinori, Spinello, et al.
Publicado: (2020)

Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
por: Sarhan, Neven Mohamed, et al.
Publicado: (2023)

Programmed Cell Death-1/Programmed Cell Death-1 Ligand as Prognostic Markers of Coronavirus Disease 2019 Severity
por: Niedźwiedzka-Rystwej, Paulina, et al.
Publicado: (2022)

Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab
por: Langer-Gould, Annette, et al.
Publicado: (2020)

Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19
por: Saha, Abinit, et al.
Publicado: (2020)

Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome
por: Oliynyk, Oleksandr, et al.
Publicado: (2021)

A Neonate With Cytokine Storm Managed With Steroids, Therapeutic Plasma Exchange, and Tocilizumab
por: LiKamWa, Amy, et al.
Publicado: (2023)

2648. Taming the Cytokine Storm: Baricitinib versus Tocilizumab for COVID-19 Hyperinflammation
por: Radziszewski, Skyler, et al.
Publicado: (2023)

Role of Tocilizumab in the Treatment of COVID-19 Patients with Cytokine Storm: A Case Series
por: Basnet, Ajaya, et al.
Publicado: (2022)

Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome
por: van Kraaij, Tom DA, et al.
Publicado: (2020)

The effect of tocilizumab on cytokine release syndrome in COVID-19 patients
por: de Cáceres, Carmen, et al.
Publicado: (2020)

Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19
por: Hassoun, Ali, et al.
Publicado: (2020)

Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence
por: Pelaia, Corrado, et al.
Publicado: (2021)

Successful treatment of acute heart failure in COVID-19-induced cytokine storm with tocilizumab: a case report
por: Chitturi, Kalyan R, et al.
Publicado: (2020)

Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome
por: Uslu, Sadettin
Publicado: (2020)

Cytokine Storm
por: Fajgenbaum, David C., et al.
Publicado: (2020)

Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab
por: Gautier-Vargas, Gabriela, et al.
Publicado: (2020)

Tocilizumab and Cytokine Release Syndrome in COVID-19 Pneumonia: Experience From a Single Center in Pakistan
por: Hassan, Muhammad, et al.
Publicado: (2021)

Cytokine Storms in the Course of COVID-19 and Haemophagocytic Lymphohistiocytosis in Pregnant and Postpartum Women
por: Obuchowska, Aleksandra, et al.
Publicado: (2021)

The Potential Role of Cytokine Storm Pathway in the Clinical Course of Viral Respiratory Pandemic
por: Murdaca, Giuseppe, et al.
Publicado: (2021)

Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm
por: Guo, Chuang, et al.
Publicado: (2020)

Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care
por: Quartuccio, Luca, et al.
Publicado: (2020)

Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers
por: Nasa, Prashant, et al.
Publicado: (2020)

Cytokine Storm in COVID-19: “When You Come Out of the Storm, You Won’t Be the Same Person Who Walked in”
por: Castelli, Vanessa, et al.
Publicado: (2020)

Calming the Cytokine Storm in Pneumonia by Biomimetic Nanoparticles
por: Xia, Yuqiong, et al.
Publicado: (2020)

The Biphasic Phenomenon of Cytokine Storm in COVID Pneumonia
por: Shah, Nehal M., et al.
Publicado: (2022)

Histamine release theory and roles of antihistamine in the treatment of cytokines storm of COVID-19
por: Eldanasory, Omar Abdelhay, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_59ag897rcgk5oeg982gsphjtcc